Pharmaceutical Executive January 12, 2024
The company also announced that it has submitted its new glucose monitoring system to the FDA for approval.
Dexcom announced that the company’s revenue for the fourth quarter of 2023 is expected to be at least $1.03 billion in a presentation at the JP Morgan Healthcare Conference. These numbers are preliminary and unaudited.
This revenue would be a 26% over the earnings of the same quarter in the previous year. Similarly, the preliminary and unaudited revenue for the fiscal year 2023 is expected to $3.62 billion.
Dexcom is a San Diego-based company that develops, manufactures, and sells continuous glucose monitoring systems for diabetes.
In a press release, Dexcom’s chairman, president, and CEO Kevin Sayer said, “Dexcom had an...
Today's Sponsors
Today's Sponsor